AI Article Synopsis
- Infectious disease physicians need to stay informed about advancements in hematopoietic cell transplant (HCT) and cellular therapies, as these can affect infection risks in immunocompromised patients.
- The review focuses on recent developments such as haploidentical transplants, their use in older patients and children, and the role of chimeric antigen receptor T-cells in managing infections.
- It also emphasizes the importance of assessing the level of immune suppression in patients to better predict and manage potential infectious complications after HCT.
Article Abstract
Background: Infectious disease physicians may be asked to evaluate and manage a variety of infections in immunocompromised hosts undergoing hematopoietic cell transplant (HCT) and cellular therapies. Over the last decade, several advances in cellular therapy have occurred, with implications for the types of infectious complications that may be seen.
Aims: The purpose of this review is to update the infectious disease physician on newer advances in HCT and cellular therapy, including haploidentical transplant, expanding indications for transplant in older individuals and children, and chimeric antigen receptor T-cells. We will review how these advances might influence infectious disease complications following HCT. We will also provide a perspective that infectious disease physicians can use to evaluate the degree of immune suppression in an individual patient to help determine the type of infections that may be encountered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/tid.14101 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!